Health Economics Analytic Support and Research Unit (HEASRU) at BC Cancer supports the BC Cancer Executive regarding decisions for the adoption and management of therapies, interventions, and technologies by performing timely economic analyses of significant challenges facing BC Cancer using the best available analysis and evidence. HEASRU also aims to engage with stakeholders to inform their evidence and recommendations, and provides health economics and outcomes research training to BC Cancer clinicians and staff. Finally, HEASRU aims to improve the methods of economic evaluation and decision-making about the funding of cancer drugs, screening programs, and technologies.
Brentuximab vedotin compared with standard therapy for patients with advanced-stage Hodgkin’s Lymphoma: a cost-effectiveness analysis
Patients with advanced Hodgkin’s Lymphoma (HL) have been with the combination of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and have largely positive outcomes.
Cost-effectiveness of stereotactic ablative radiotherapy (SABR) for patients with oligometastatic cancers
Stereotactic ablative radiotherapy (SABR) may offer potential benefit for patients with oligometastatic cancers. The SABR technology is still evolving, and there is still uncertainty about whether or not this treatment will be effective.
An economic evaluation of prostate cancer screening using prostate specific antigen in British Columbia
Detecting prostate cancer early in men at risk is of prostate cancer can potentially improve outcomes. Prostate specific antigen (PSA) testing, however, has been shown to not be an effective method of detecting prostate cancer in the population.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.